NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 166)
Posted On: 12/16/2022 3:44:26 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raid $8M
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit consists of one American Depositary Share (“ADS”) and two warrants; one warrant will expire three years from the date of issuance with the second warrant set to expire one year from the date of issuance. Each ADS (or prefunded warrant) is being sold with two warrants at $5 per unit. According to the company, the funds raised will be used to develop its NanoAbs program along with general corporate purposes, including working capital, R&D activities, regulatory matters, capital investment and other related purposes. Aegis Capital Corp. is acting as sole book-running manager for the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the pricing of its underwritten public offering. According to the announcement, the company anticipates gross proceeds from the offering, which consists of 1,600,000 units and prefunded units, to reach an estimated $8 million. The company specified that each unit consists of one American Depositary Share (“ADS”) and two warrants; one warrant will expire three years from the date of issuance with the second warrant set to expire one year from the date of issuance. Each ADS (or prefunded warrant) is being sold with two warrants at $5 per unit. According to the company, the funds raised will be used to develop its NanoAbs program along with general corporate purposes, including working capital, R&D activities, regulatory matters, capital investment and other related purposes. Aegis Capital Corp. is acting as sole book-running manager for the offering.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)